Valsartan Intensified Primary Care Reduction of Blood Pressure Study

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Collaborators: Baker Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
• Treatments: Amlodipine; Amlodipine, Valsartan Drug Combination; Hydrochlorothiazide; Valsartan

Criteria

Inclusion Criteria:

• newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner

Exclusion Criteria:

• significantly elevated blood pressure (severe hypertension)

• requiring 3 or more antihypertensive drugs

• severe kidney disease or dialyses

• clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol

Other protocol-defined inclusion/exclusion criteria may apply